-
Product Insights
PFR RE – Legionów Residential Complex – Warmian-Masurian Voivodeship
The PFR RE – Legionów Residential Complex – Warmian-Masurian Voivodeship involves the construction of an eight-story residential complex comprising 148 homes in Elblag, Warmian-Masurian Voivodeship, Poland. Equip yourself with the essential tools needed to make informed and profitable decisions with our PFR RE – Legionów Residential Complex – Warmian-Masurian Voivodeship report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and...
-
Product Insights
Greystar RE – Marlowe Peoria Place Residential Community – Arizona
The Greystar RE – Marlowe Peoria Place Residential Community – Arizona involves the construction of a three-story community with 370 apartment homes in Peoria, Arizona, the US. Equip yourself with the essential tools needed to make informed and profitable decisions with our Greystar RE – Marlowe Peoria Place Residential Community – Arizona report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Liafensine in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Liafensine in Treatment Resistant Depression report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Liafensine in Treatment Resistant Depression Drug Details: Liafensine (DB-104) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Primary Sjogren’s Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Primary Sjogren's Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Primary Sjogren's Syndrome Drug Details: Frexalimab (INX-021) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Relapsing Remitting Multiple Sclerosis (RRMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zonisamide in Hearing Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zonisamide in Hearing Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zonisamide in Hearing Disorders Drug Details: Zonisamide (GW-2) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-014 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-014 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-014 in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PB-101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PB-101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PB-101 in Solid Tumor Drug Details: PB-101 is under development for...